For ethical and cost-related reasons, use of animals for the assessment of mode of action, metabolism and/or toxicity of new drug candidates has been increasingly scrutinized in research and industrial applications. Physiologically based pharmacokinetic (PBPK2) modeling is the most potent in silico tool used for extrapolation of pharmacokinetic parameters to animal or  human models from results obtained in vitro. Two dimensional (2D) cell cultures have been a part of drug development for many years.

Nowadays, their role is decreasing in favor of three-dimensional (3D) cell cultures and co-cultures. 3D cultures exhibit protein expression patterns and intercellular junctions that are closer to in vivo states in comparison to classical monolayer cultures. In vitro absorption, distribution, metabolism, and excretion assessment, as well as drug-drug interaction (DDI), are usually performed with the use of various cell culture based assays. Progress in in silico and in vitro methods can lead to better in vitro-in vivo extrapolation (IVIVE) outcomes and have a potential to contribute towards a significant reduction in the number of laboratory animals needed for drug research. As such, concentrated efforts need to be spent towards the development of an HTS in vitro platform with satisfactory IVIVE features.

Source : https://www.ncbi.nlm.nih.gov/pubmed/28811111

Cell biology is part of the R&D activity in dermocosmetology, as providers of active extracts or pure compounds have to demonstrate their efficacy and safety. At HCS Pharma, we are developing new dermocosmetology assays on relevant cellular models, like human primary keratinocytes and human primary fibroblasts, using our automated platform and high content analysis system. Through the use of 96 or 384 wells plates combined with process automation, we constantly increase the throughput in order to allow proof of concept assays of one or several compounds up to the screening of large compounds libraries, for single endpoint or live cells analysis to multiplexed phenotypic screening.
Assessment of compounds activity/safety can be performed on several parameters in parallel with a multiplexed assay. Among them, we describe here wound healing, inflammation assay & extra cellular matrix analysis, which are routinely performed. Other parameters can be analysed on demand on live and fixed cells, using chemical probes or immunocytochemistry.

View and download on Slideshare (low quality) : https://www.slideshare.net/hcspharma/in-vitro-dermocosmetology-high-content-analysis-approach-using-human-primary-keratinocytes-and-fibroblasts

Ask for high quality link  by putting your email below

A very interesting talk will be done by Marc Pissavini in next Cosmeticdays (1st and 2nd December in Marseille). If it’s clear that in vivo methods must be replaced for sunscreen products, the standardization process of SPF (Sun Protection Factor) need to be adapted ans standardized.

There is no doubt, we have to replace in vivo methods by in vitro methods for sunscreen products. Whether for economic or ethical reasons, thanks to manufacturers, under pressure from the associations, from the European commission, health or security agencies, the consensus is clear, the next developed method must be an in vitro one.

Source: Premium Beauty News – In vitro method in sun care, a status

ESTIV conference, named In Vitro Toxicology for Human Safety Assessment, takes place this week in Juan-les-Pins. This congress brings together a lot of toxicologists, from public and private, to discuss the last development of predictive in vitro models in safety testing, as 3D models, organ-on-a-chip, bioprint organs.

To learn more and to exchange on these topics, Julian, our COO, is present to this conference. Have a nice time to discuss with him on these last development of in vitro safety testing models ! If you want to be contacted, please leave your mobile number here :

%d bloggers like this: